ARL8B Knockout A-549 Polyclonal Cells represent a CRISPR/Cas9-edited polyclonal knockout cell population for investigating ARL8B function. This heterogeneous A-549 pool carries targeted gene disruptions, enabling loss-of-function studies without clonal isolation. The polyclonal format preserves population diversity while abolishing ARL8B activity, allowing robust comparisons with wild-type controls. These cells provide a versatile system to dissect lysosomal dynamics free from incomplete knockdown artifacts, suitable for applications in cancer biology and beyond.
The host A-549 cell line, derived from a 58-year-old Caucasian male with lung adenocarcinoma, is a widely used model for non-small cell lung cancer (NSCLC) and alveolar type II pneumocyte biology. These adherent epithelial cells support investigations into oncogenic signaling, metabolic programming, and vesicular trafficking. Their established genetic background and relevance to lung tumorigenesis make them an ideal platform for studying the consequences of ARL8B disruption on lysosomal homeostasis and cancer cell behavior.
ARL8B encodes a lysosome-anchored small GTPase that orchestrates anterograde lysosomal transport. Activated by the BORC complex and mTORC1 signaling, ARL8B recruits kinesin-1 motors, including KIF5B, through interactions with the adaptor SKIP (PLEKHM2) and kinesin light chain, promoting peripheral lysosome movement. This spatial regulation influences mTOR activity, autophagy, and lysosomal exocytosis. Upstream regulators such as Rab7 and RILP modulate ARL8B function, while dynein components balance retrograde trafficking. ARL8B also interacts with BORC subunits and downstream lysosomal membrane proteins, integrating nutrient availability with organelle positioning. Disruption of this network impairs endosomal transport and autophagic degradation.
In the context of A-549 lung adenocarcinoma cells, ARL8B knockout provides a powerful model to examine how lysosomal positioning contributes to cancer invasion and metabolic adaptation. Aberrant lysosomal trafficking is linked to enhanced migration and mTORC1 hyperactivation in NSCLC, making this tool pivotal for mechanistic studies. Additionally, the model may recapitulate lysosomal dysfunction relevant to neurodegenerative and lysosomal storage disorders. By eliminating ARL8B in an epithelial cancer background, researchers can probe intersections between lysosome biology and oncogenic pathways, potentially uncovering novel therapeutic vulnerabilities.
Common applications include immunofluorescence to assess lysosomal distribution, Western blotting for ARL8B and mTOR pathway targets (e.g., phospho-S6K, LC3-II), quantitative migration and invasion assays, and autophagy flux measurements using LC3-II turnover with lysosomal inhibitors. Lysosomal exocytosis can be monitored via ??-hexosaminidase release. These approaches enable phenotypic characterization, pharmacological screening for lysosomal trafficking modulators, and disease modeling. For more information, please contact Ascent Research.
